Leber hereditary optic neuropathy: current perspectives

C Meyerson, G Van Stavern… - Clinical …, 2015 - Taylor & Francis
C Meyerson, G Van Stavern, C McClelland
Clinical Ophthalmology, 2015Taylor & Francis
Leber hereditary optic neuropathy (LHON) is one of the most common inherited optic
neuropathies causing bilateral central vision loss. The disorder results from point mutations
in mitochondrial DNA and subsequent mitochondrial dysfunction. The primary cell type that
is lost in LHON is the retinal ganglion cell, which is highly susceptible to disrupted ATP
production and oxidative stress. Inheritance of LHON follows that of mitochondrial genetics,
and it has a highly variable clinical phenotype, as other genetic and environmental factors …
Leber hereditary optic neuropathy (LHON) is one of the most common inherited optic neuropathies causing bilateral central vision loss. The disorder results from point mutations in mitochondrial DNA and subsequent mitochondrial dysfunction. The primary cell type that is lost in LHON is the retinal ganglion cell, which is highly susceptible to disrupted ATP production and oxidative stress. Inheritance of LHON follows that of mitochondrial genetics, and it has a highly variable clinical phenotype, as other genetic and environmental factors also play a role. Although LHON usually presents with isolated vision loss, some patients suffer other neurological sequelae. For ill-defined reasons, male LHON mutation carriers are more affected than females. Most LHON patients remain legally blind, but a small proportion can experience spontaneous partial recovery, often within the first year of symptom onset. Unfortunately, at this time there are no established curative interventions and treatment is largely supportive. Patients should be offered low vision services and counseled on mitigating risk factors for additional vision loss, such as smoking and consuming alcohol. Encouraging treatments currently undergoing investigation includes ubiquinone analogs, such as idebenone, as well as gene therapy and stem cells to restore ATP synthesis and provide neuroprotection to surviving retinal ganglion cells.
Taylor & Francis Online